American Well Corp
American Well Corp provides digital health services, including virtual care platforms and telehealth solutions, primarily generating revenue through subscription and service fees.
Business. American Well Corp (NYSE: AMWL) is a healthcare services company that operates within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models, focusing on healthcare delivery and related services. American Well is headquartered in the United States and is primarily listed on the New York Stock Exchange under the ticker symbol AMWL. Specific operating segments and geographic breakdowns are not disclosed in the available data.
Analyst recommendations
9 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
American Well Corp (NYSE: AMWL) is a healthcare services company that operates within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models, focusing on healthcare delivery and related services. American Well is headquartered in the United States and is primarily listed on the New York Stock Exchange under the ticker symbol AMWL. Specific operating segments and geographic breakdowns are not disclosed in the available data.
American Well operates with a highly liquid capital structure, as evidenced by $276.9 million in cash and equivalents, which significantly exceeds its total liabilities of $143.9 million, resulting in a current ratio of 3.21. The company's price-to-book ratio of 0.36 and price-to-tangible-book ratio of 0.36 indicate that the market values the company at a substantial discount to its book value. Despite this, the company has no long-term debt, which reduces its financial leverage and exposure to interest rate risk.
Profitability metrics are negative, with a return on equity of -13.72% and a return on assets of -9.83%, both well below industry norms. The company reported a net loss of $49.9 million and an operating loss of $52.4 million, indicating ongoing operational challenges. Gross profit of $23.5 million suggests some margin generation, but it is insufficient to offset operating expenses.
Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, but the absence of segment-specific revenue breakdowns implies a lack of diversification. This could pose a risk if demand in its primary market or service line declines.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the negative operating and free cash flows of -$81.5 million and -$46.8 million, respectively, suggest that the company is not generating sufficient cash to fund operations or expansion. The capital expenditure of -$8.1 million indicates some investment in infrastructure, but it is minimal relative to the company's overall financial position.
Risk factors include the company's negative net income and operating income, which could affect its ability to sustain operations without external financing. The risk assessment indicates low liquidity and dilution risk, but the absence of long-term debt does not eliminate the need for ongoing cash flow management. No immediate filing-based liquidity or dilution flags were detected, but the company's financial performance suggests a need for continued monitoring.
Recent events, including analyst estimates, show a mean price target of $6.50 and a median of $5.50, with a mean recommendation of 2.89, indicating a generally cautious outlook. The lack of strong buy ratings and the presence of eight hold ratings suggest that analysts are not optimistic about the company's near-term prospects.
- American Well has a highly liquid balance sheet with $276.9 million in cash and equivalents, but it is not generating positive operating cash flow.
- The company's profitability metrics are negative, with a return on equity of -13.72% and a return on assets of -9.83%.
- The company's market valuation is significantly below book value, as indicated by a price-to-book ratio of 0.36.
- Analysts have a generally cautious outlook, with a mean price target of $6.50 and a mean recommendation of 2.89.
- The company's financial performance suggests a need for continued monitoring of liquidity and operational efficiency.
Bull / Bear case
Generated · model-assistedFree cash flow improved by 69.1% year-over-year to -$59.3 million in FY2026, signaling significant operational efficiency gains.
The company maintains a zero long-term debt position, providing a strong balance sheet with no interest obligations.
Gross profit increased to $134.1 million in FY2026, demonstrating an ability to generate top-line margin despite revenue declines.
Net income losses narrowed by 54.0% year-over-year to -$95.7 million in FY2026, indicating a clear path toward profitability.
Cash conversion ratio of 1.63 exceeds the healthcare facilities cohort median of 1.36, suggesting superior cash management.
Revenue declined 0.3% annually over four years, falling to $249.3 million in FY2026, indicating persistent top-line stagnation.
Return on equity of -13.7% ranks in the bottom quartile, reflecting poor capital efficiency compared to peers.
The company carries a high credit risk flag, suggesting potential difficulties in securing favorable financing terms.
In focus — financials by report
Revenue $54.9M, −17,9% YoY.
- ▍Revenue $54.9M, −17,9% YoY
Revenue $55.3M, −22,1% YoY; Operating income +38,6% YoY.
- ▍Revenue $55.3M, −22,1% YoY
- ▍Operating income +38,6% YoY
- ▍Net income +41,6% YoY
- ▍Free cash flow +56,7% YoY
- ▍Net margin -45.1%
Revenue $56.3M, −7,8% YoY; Operating income +33,9% YoY.
- ▍Revenue $56.3M, −7,8% YoY
- ▍Operating income +33,9% YoY
- ▍Net income +25,5% YoY
- ▍Free cash flow +43,5% YoY
- ▍Net margin -57.5%
Revenue $70.9M, +12,9% YoY; Operating income +61,1% YoY.
- ▍Revenue $70.9M, +12,9% YoY
- ▍Operating income +61,1% YoY
- ▍Net income +60,5% YoY
- ▍Free cash flow +77,4% YoY
- ▍Net margin -27.8%
Revenue $66.8M; Operating income -$19.7M.
- ▍Revenue $66.8M
- ▍Operating income -$19.7M
- ▍Net margin -28.0%
Revenue $71.0M; Operating income -$42.8M.
- ▍Revenue $71.0M
- ▍Operating income -$42.8M
- ▍Net margin -60.1%
Revenue $61.0M; Operating income -$47.4M.
- ▍Revenue $61.0M
- ▍Operating income -$47.4M
- ▍Net margin -71.2%
Revenue $62.8M; Operating income -$52.4M.
- ▍Revenue $62.8M
- ▍Operating income -$52.4M
- ▍Net margin -79.5%
Revenue $249.3M, −2,0% YoY; Operating income +55,1% YoY.
- ▍Revenue $249.3M, −2,0% YoY
- ▍Operating income +55,1% YoY
- ▍Net income +54,0% YoY
- ▍Free cash flow +69,1% YoY
- ▍Net margin -38.4%
Revenue $254.4M, −1,8% YoY; Operating income +68,6% YoY.
- ▍Revenue $254.4M, −1,8% YoY
- ▍Operating income +68,6% YoY
- ▍Net income +69,2% YoY
- ▍Free cash flow +71,0% YoY
- ▍Net margin -81.8%
Revenue $259.0M, −6,5% YoY; Operating income −150,9% YoY.
- ▍Revenue $259.0M, −6,5% YoY
- ▍Operating income −150,9% YoY
- ▍Net income −149,7% YoY
- ▍Free cash flow −159,9% YoY
- ▍Net margin -260.6%
Revenue $277.2M, +9,7% YoY; Operating income −54,0% YoY.
- ▍Revenue $277.2M, +9,7% YoY
- ▍Operating income −54,0% YoY
- ▍Net income −53,4% YoY
- ▍Free cash flow −60,7% YoY
- ▍Net margin -97.6%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -4,24 |
| Revenue | —no estimate | —no estimate | 199,4M USD |
| Operating income | —no estimate | —no estimate | -73,1M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- American Well Corp Market data — financials · 2026-05-27
- American Well Corp Market data — analyst estimates · 2026-05-27
- American Well Corp Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director · Class A Common StockOther 14 501 · 2026-06-16
- Director · Class A Common StockOther 14 501 · 2026-06-16
- Director · Class A Common StockOther 14 501 · 2026-06-16
- Director · Class A Common StockOther 14 501 · 2026-06-16
- Director · Class A Common StockOther 14 501 · 2026-06-16
- Director · Class A Common StockOther 14 501 · 2026-06-16
- Director · Class A Common StockSold 9 750 @ $8,76$85K · 2026-06-11
- Chief Financial Officer · Class A Common StockSold 10 761 @ $9,74$105K · 2026-06-01
- Chief Accounting Officer · Class A Common StockSold 112 @ $9,74$1K · 2026-06-01
- President, International · Class A Common StockSold 3 573 @ $9,74$35K · 2026-06-01
- Director, Chairman, co-CEO · Class A Common StockBought 670 @ $7,37$5K · 2026-05-07
- Chief Accounting Officer · Class A Common StockSold 383 @ $5,30$2K · 2026-04-01
- Chief Product & Tech. Officer · Class A Common StockSold 5 575 @ $5,30$30K · 2026-04-01
- President, International · Class A Common StockSold 3 706 @ $5,30$20K · 2026-04-01
- Chief Product & Tech. Officer · Class A Common StockOther 50 413 · 2026-03-04
- Chief Accounting Officer · Class A Common StockOther 8 066 · 2026-03-04
- Chief Financial Officer · Class A Common StockOther 50 413 · 2026-03-04
- President, International · Class A Common StockOther 50 413 · 2026-03-04
- Chief Financial Officer · Class A Common StockSold 10 796 @ $5,24$57K · 2026-03-02
- Chief Product & Tech. Officer · Class A Common StockSold 2 472 @ $5,45$13K · 2026-03-02
- President, International · Class A Common StockSold 3 573 @ $5,24$19K · 2026-03-02
- Chief Accounting Officer · Class A Common StockSold 130 @ $5,24$681 · 2026-03-02
- Chief Product & Tech. Officer · Class A Common StockSold 6 243 @ $4,85$30K · 2026-01-02
- Chief Accounting Officer · Class A Common StockSold 384 @ $4,85$2K · 2026-01-02
- President, International · Class A Common StockSold 3 707 @ $4,85$18K · 2026-01-02
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Capex (YoY) (2025-12-31 vs 2024-12-31): -82.4%Derived (calculated)
- Net margin (FY 2025-12-31): -38.4%Derived (calculated)
- Return on equity (FY 2025-12-31): -40.6%Derived (calculated)
- Return on assets (FY 2025-12-31): -29.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 3.37xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.32xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -20.1%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 54.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 48.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 51.6%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -15.3%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -2.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -22.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -25.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -36.5%Derived (calculated)
- Cash & equivalents (annual): USD 182.33MSEC XBRL filing
- Shareholders' equity (annual): USD 235.58MSEC XBRL filing
- Pre-tax income (annual): USD -94.53MSEC XBRL filing
- Capex (annual): USD 21KSEC XBRL filing
- Net income (annual): USD -95.7MSEC XBRL filing
- Current assets (annual): USD 246.68MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -6SEC XBRL filing